METTL3-associated m6A modification of IGF2 promotes a diabetic vascular calcification phenotype in endothelial cells
4 affiliations
- 1Department of General Practice, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, China
- 2Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University, Guilin, Guangxi, China
- 3Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China
- 4Department of General Practice, Third Affiliated Hospital of Shenzhen University and State Key Laboratory of Respiratory Diseases, Allergy Division, Shenzhen University, Shenzhen, China
Abstract
Diabetic vascular calcification involves endothelial-to-mesenchymal transition (EndMT) and osteogenic differentiation; however, the underlying regulatory mechanisms remain poorly defined. This study aims to investigate the role of the RNA methyltransferase METTL3 in mediating m6A modifications that promote EndMT and osteogenic differentiation. Human aortic endothelial cells (HAECs) were exposed to high glucose (HG) and osteogenic media conditions to recapitulate diabetic vascular endothelial dysfunction and osteogenic differentiation. We investigated the mRNA and protein expression of EndMT and osteogenic markers. Loss-of- and gain-of-function studies, supplemented by rescue experiments, were used to characterize the underlying molecular mechanisms. HG-treatment increased the expression of METTL3, global m6A levels, and markers of EndMT. Under HG and osteogenic conditions, METTL3 deficiency significantly alleviated the EndMT and calcification phenotype in HAECs. Consistent with this, Western blot analysis confirmed that METTL3 promotes PI3K-Akt pathway activation, thereby driving the EndMT. We subsequently found that METTL3 and IGF2BP2 stabilize IGF2 mRNA, suggesting an m6A-dependent mechanism. This upregulation of IGF2 promotes EndMT and osteogenic differentiation by activating the PI3K-Akt pathway under diabetic osteogenic conditions. By further investigating the post-transcriptional regulation of IGF2 expression, we found that METTL3 stabilizes IGF2 mRNA through an IGF2BP2-dependent mechanism. METTL3-mediated m6A modification promotes the diabetic vascular calcification phenotype in HAECs by stabilizing IGF2 mRNA, activating the PI3K‑Akt pathway, and driving endothelial-to-osteogenic transition. Our data suggest that endothelial cells may actively participate in diabetic vascular calcification through transdifferentiation processes. These findings suggest that METTL3 may be a potential therapeutic target in diabetic vascular calcification, warranting further validation.
Related
- Endothelial EV-derived miR-122b-3p suppresses autophagy via FOXP1/FUT8- dependent core fucosylation in uremic coronary artery calcification
- The Senokine Gas6 Promotes Aortic Valve Calcification Through CaMKII-DRP1-Mediated Terminal Scission of Mitochondrial-Derived Vesicles.
- ALYREF regulates glycolysis and promotes the progression of endometrial cancer through m5C modification of PKM2 mRNA
- O-GlcNAc Modification of CEBPB Promotes Astrocytic Pyroptosis by Activating NLRP3 Inflammasome Through Transcriptional Activation of IKKβ
- Queuosine-modification dependent histidyl tRNA fragment promotes cell-type dependent proliferation
BibTeX
@article{sammad2026mettl3associated,
title = {{METTL3-associated m6A modification of IGF2 promotes a diabetic vascular calcification phenotype in endothelial cells}},
author = {Abdul Sammad and Jin-Feng Qin and Duan Meng and Sohrab Khan and Xiao Zhu and Kai Yin},
journal = {Epigenetics},
year = {2026},
month = nov,
doi = {10.1080/15592294.2026.2744043},
url = {https://doi.org/10.1080/15592294.2026.2744043},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - METTL3-associated m6A modification of IGF2 promotes a diabetic vascular calcification phenotype in endothelial cells
AU - Abdul Sammad
AU - Jin-Feng Qin
AU - Duan Meng
AU - Sohrab Khan
AU - Xiao Zhu
AU - Kai Yin
PY - 2026
DA - 2026/11/05
JO - Epigenetics
DO - 10.1080/15592294.2026.2744043
UR - https://doi.org/10.1080/15592294.2026.2744043
AB - Diabetic vascular calcification involves endothelial-to-mesenchymal transition (EndMT) and osteogenic differentiation; however, the underlying regulatory mechanisms remain poorly defined. This study aims to investigate the role of the RNA methyltransferase METTL3 in mediating m6A modifications that promote EndMT and osteogenic differentiation. Human aortic endothelial cells (HAECs) were exposed to high glucose (HG) and osteogenic media conditions to recapitulate diabetic vascular endothelial dysfunction and osteogenic differentiation. We investigated the mRNA and protein expression of EndMT and osteogenic markers. Loss-of- and gain-of-function studies, supplemented by rescue experiments, were used to characterize the underlying molecular mechanisms. HG-treatment increased the expression of METTL3, global m6A levels, and markers of EndMT. Under HG and osteogenic conditions, METTL3 deficiency significantly alleviated the EndMT and calcification phenotype in HAECs. Consistent with this, Western blot analysis confirmed that METTL3 promotes PI3K-Akt pathway activation, thereby driving the EndMT. We subsequently found that METTL3 and IGF2BP2 stabilize IGF2 mRNA, suggesting an m6A-dependent mechanism. This upregulation of IGF2 promotes EndMT and osteogenic differentiation by activating the PI3K-Akt pathway under diabetic osteogenic conditions. By further investigating the post-transcriptional regulation of IGF2 expression, we found that METTL3 stabilizes IGF2 mRNA through an IGF2BP2-dependent mechanism. METTL3-mediated m6A modification promotes the diabetic vascular calcification phenotype in HAECs by stabilizing IGF2 mRNA, activating the PI3K‑Akt pathway, and driving endothelial-to-osteogenic transition. Our data suggest that endothelial cells may actively participate in diabetic vascular calcification through transdifferentiation processes. These findings suggest that METTL3 may be a potential therapeutic target in diabetic vascular calcification, warranting further validation.
SN - 1559-2294
SN - 1559-2308
ER -